Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer
Industry veteran and experienced CEO will continue to lead the company as its AAV-based gene therapies for inherited retinal diseases approach the clinic » Full Release
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients » Full Release
Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
Retinal regions of preserved photoreceptors identified as targets for subretinal delivery of AAV8-based gene therapy to address mutations in genes that cause forms of Leber congenital amaurosis » Full Release
New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022
Data support the continued development of OPGx-001 and OPGx-002 to address mutations in genes causing forms of Leber congenital amaurosis » Full Release
Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseases
 Opus’ first-in-human trials to begin in 2022 » Full Release
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
20-year biopharma industry veteran to lead manufacturing for Opus’ AAV-based gene therapies for inherited retinal diseases RALEIGH, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) — Opus ... » Full Release
Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease
Program targets NMNAT1 gene based on the work of Opus scientific founder Dr. Eric Pierce RALEIGH, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) — Opus Genetics, ... » Full Release
Opus Genetics Announces Presence at Eyecelerator@AAO 2021
ALEIGH, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced that ... » Full Release
Opus Genetics Announces Two Key Leadership Appointments
Dr. Ash Jayagopal named Chief Scientific Officer Mr. Joe Schachle appointed Chief Operating Officer RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) — Opus Genetics, a ... » Full Release
RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions
Initial programs will focus on treatments for rare pediatric blinding conditions Company formed to advance the work of scientific cofounders Dr. Jean Bennett, Junwei Sun ... » Full Release